Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.9 - $8.02 $147,500 - $200,500
25,000 Added 3.45%
750,000 $4.89 Million
Q1 2024

May 15, 2024

BUY
$7.5 - $12.07 $937,500 - $1.51 Million
125,000 Added 20.83%
725,000 $6.02 Million
Q4 2023

Feb 14, 2024

SELL
$6.01 - $11.48 $1.2 Million - $2.3 Million
-200,000 Reduced 25.0%
600,000 $6.61 Million
Q3 2023

Nov 14, 2023

BUY
$8.24 - $12.97 $824,000 - $1.3 Million
100,000 Added 14.29%
800,000 $6.73 Million
Q2 2023

Aug 11, 2023

SELL
$9.99 - $18.27 $699,300 - $1.28 Million
-70,000 Reduced 9.09%
700,000 $8.79 Million
Q1 2023

May 09, 2023

BUY
$15.0 - $22.76 $2.18 Million - $3.3 Million
145,000 Added 23.2%
770,000 $12.7 Million
Q4 2022

Feb 13, 2023

BUY
$14.16 - $24.02 $354,000 - $600,500
25,000 Added 4.17%
625,000 $9.34 Million
Q3 2022

Nov 14, 2022

BUY
$18.07 - $31.37 $2.96 Million - $5.14 Million
163,738 Added 37.53%
600,000 $13.4 Million
Q2 2022

Aug 03, 2022

BUY
$13.31 - $34.88 $1.45 Million - $3.81 Million
109,262 Added 33.41%
436,262 $7.31 Million
Q1 2022

May 12, 2022

BUY
$20.26 - $32.36 $2.07 Million - $3.3 Million
102,000 Added 45.33%
327,000 $9.79 Million
Q4 2021

Feb 02, 2022

BUY
$26.0 - $37.03 $2.21 Million - $3.15 Million
85,000 Added 60.71%
225,000 $6.91 Million
Q3 2021

Nov 12, 2021

BUY
$29.75 - $37.99 $595,000 - $759,800
20,000 Added 16.67%
140,000 $4.41 Million
Q2 2021

Aug 30, 2021

SELL
$27.5 - $38.19 $3.3 Million - $4.58 Million
-120,000 Reduced 50.0%
120,000 $4.39 Million
Q2 2021

Aug 13, 2021

BUY
$27.5 - $38.19 $4.95 Million - $6.87 Million
180,000 Added 300.0%
240,000 $8.78 Million
Q1 2021

May 10, 2021

BUY
$32.52 - $61.53 $1.95 Million - $3.69 Million
60,000 New
60,000 $2.07 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $535M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Integral Health Asset Management, LLC Portfolio

Follow Integral Health Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Integral Health Asset Management, LLC with notifications on news.